Topics

FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer

13:27 EDT 13 Sep 2019 | OncLive

The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs.

Original Article: FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer"

Quick Search